Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in Patients With STEMI

Recruiting now · Phase 2

Conditions studied: Reperfusion Injury, Myocardial, Myocardial Infarction

In brief

The study aims is to evaluate the efficacy and tolerability of L-Carnitine on biomarkers of myocardial reperfusion injury in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI by the assessment of nitrotyrosine as an oxidative stress marker and Matrix metallopeptidase-2 (MMP-2) as a cardiac fibrosis marker

Key facts

Study ID: NCT06564909
Run by: Ain Shams University
People needed: 76
Starts: 2025-06-01
Expected to finish: 2026-03-01
Last updated by the study team: 2025-06-26

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Female or male aged >18 and < 75 years.
STEMI patients undergoing PCI.

You may not qualify if…

Patients with a recent history of myocardial infarction (MI), a previous PCI, a previous coronary artery bypass graft, or any cardiac surgery.
A late presentation (>12 h), unsuccessful primary PCI (residual stenosis >50% in the culprit lesion after procedure),
Pretreatment with thrombolytic or glycoprotein IIb/IIIa inhibitor therapy before primary PCI,
Concurrent Infectious or active inflammatory disease,
Severe liver or renal disease, (aspartate aminotransferase (AST) or alanine transaminase (ALT) > 3x ULN or Total bilirubin > 3 x ULN), (CrCl < 60 ml/min (based on the Cockroft-Gault equation)
Neoplasm, or hematological disorders
Pregnant or breast-feeding patients
Active participation in another clinical study
Patients taking antioxidant drugs.
History of or known allergy or intolerability to the study medications

Where it is running

Ain Shams University Hospitals — Cairo, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.